Edwards Declares Victory In CardiAQ Lawsuit Vs Neovasc
This article was originally published in Clinica
A jury in Boston has recommended that Neovasc pay CardiAQ, now part of Edwards Lifesciences, $70m in damages to resolve a two-year old intellectual property lawsuit, Edwards announced May 19.
You may also be interested in...
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
In this week’s podcast, Marion Webb reviews her interview with Glooko CEO Russ Johannesson and Reed Miller explains how Boston Scientific is restructuring its transcatheter aortic valve business.